preventive measures. When a drug is selected to prevent the resistant forms of P.
falciparum, that same drug will prevent malaria from the other species that could be
It is not necessary to use one drug for P. falciparum and a different drug for
the other species of malaria.
d. Disease Control and Prevention Recommendations. In general, the U.S.
military has formally decided to follow recommendations of the Disease Control and
Prevention (CDC, Atlanta, GA) concerning the choice of drugs for a particular area of
the world. The CDC publishes a number of documents related to precautions for
travelers and uses the publication entitled the "Weekly Morbidity and Mortality Report"
(WMMR) to publish updates on this topic.
e. The Final Decision on the Appropriate Drug. The unit or installation
medical officer should make the final decision regarding the appropriate suppressive
drug for the area and type of deployment or travel.
That decision should be based on many variables and made only after
consultation with the Disease Control Consultant at the Office of the Surgeon General of
the Army (OTSG).
Medical authorities recommend appropriate actions.
Figure 5-7. Prevent mosquito-borne disease.
f. Plan for Troops Exposed to Malaria.
While all four of the human malarias cause an acute illness, the disease
caused by either P. vivax or P. ovate can relapse after treatment and recovery from the
acute illness. Simple treatment of these forms of malaria will not prevent their return.
Wherever troops are exposed to malaria, it is necessary that they receive
a course of the drug primaquine to kill the liver stage of the parasite that may be present
and may continue to develop and cause disease at a later date. The exact dose and
timing of the course is determined by the responsible physician or Preventive Medicine